3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Purpura, Thrombotic Thrombocytopenic
1
Purpura, Thrombocytopenic, Idiopathic
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Leukemia
1
COVID-19
1
Interventions
Cyclophosphamide
61
fludarabine phosphate
52
Peripheral Blood Stem Cell Transplantation
41
Busulfan
41
Tacrolimus
36
Antilymphocyte Serum
34
Mycophenolic Acid
33
Radiotherapy
30
Melphalan
27
Filgrastim
27
Cyclosporine
25
Methotrexate
23
Whole-Body Irradiation
21
fludarabine
20
Methylprednisolone
18
Etoposide
17
Cord Blood Stem Cell Transplantation
15
sargramostim
10
Cytarabine
10
Rituximab
9
Alemtuzumab
9
Sirolimus
8
Granulocyte Colony-Stimulating Factor
8
Epoetin Alfa
7
Carmustine
7
Stem Cell Transplantation
6
Psychiatric Rehabilitation
6
Prednisone
6
Flow Cytometry
6
Trimethoprim, Sulfamethoxazole Drug Combination
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Plasma Cell
×
ogalvibart
×
Other hematologic neoplasm
×
Clear all
NCT05393999
2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2
Withdrawn